Genetic polymorphism of CYP2D6 in patients with systemic lupus erythematosus and systemic sclerosis

Autoimmunity

Volumn 49, Issue 3, 2016, Pages 166-171

  Barańska, Małgorzata ^a   Rychlik Sych, Mariola ^a   Kaszuba, Andrzej ^a   Dziankowska Bartkowiak, Bożena ^a   Skrętkowicz, Jadwiga ^a   Waszczykowska, Elżbieta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Autoimmune diseases; cytochrome P 450; genotypes; oxidation; xenobiotics

Indexed keywords

EID: 84955115806     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2015.1134508     Document Type: Article

References (38)

1. Ledesma, M. C., and J. A. G. Agundez. 2005. Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication. Clin. Chem. 51: 939–943
2. Lopez, M., J. Guerrero, H. Jung-Cook, and M. E. Alonso. 2005. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. Eur. J. Clin. Pharmacol. 61: 749–754
3. Wong, J. Y., E. S. Seah, and E. J. Lee. 2000. Pharmacogenetics: the molecular genetics of CYP2D6 dependent drug metabolism. Ann. Acad. Med. Singapore. 29: 401–406
4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Available from: www.cypalleles.ki.se.
5. Skrętkowicz, J., and M. Rychlik-Sych. 2008. [Polimorphism of cytochrome P-450]. Farm. Pol. 64: 61–72
6. Ingelman-Sundberg, M. 2004. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends. Pharmacol. Sci. 25: 193–200
7. Nambiar, M. P., Y.T. Juang, S. Krishanan, and G. C. Tsocos. 2004. Dissecting the molecular mechanisms of TCR ζ chain downregulation and T cell signaling abnormalities in human systemic lupus erythematosus. Int. Rev. Immunol. 23: 245–263
8. Horiuchi, T., M. Washio, Ch. Kiyohara, et al. Kyushu Sapporo SLE Study Group. 2009. Combination of TNF-RII, CYP1A1 and GSTM1 polymorphisms and the risk of Japanese SLE: findings from the KYSS study. Rheumatology 48: 1045–1049
9. Valentini, G. 2003. The assessment of the patent with systemic sclerosis. Autoimmun. Rev. 2: 37–376
10. Tikly, M., S. E. Marshall, N. A. Haldar, et al. 2004. Oxygen free radical scavenger enzyme polymorphisms in systemic sclerosis. Free. Radic. Biol. Med. 36: 1403–1407
11. Fonesca, C., G. E. Lindahl, M. Ponticos, et al. 2007. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N. Engl. J. Med. 357: 1210–1220
12. O'Reilly, S. 2015. miRNA-29a in systemic sclerosis: a valid target. Autoimmunity 3: 1–2
13. Raman, K., and C. Mohan. 2003. Genetic underpinnings of autoimmunity-lessons from studies in arthritis, diabetes, lupus and multiple sclerosis. Curr. Opin. Immunol. 15: 651–659
14. Kim, R., M. Emi, and K. Tanabe. 2006. Cancer immunosupresion and autoimmune disease: beyond immunosuppressive networks for tumor immunity. Immunology. 119: 254–264
15. Li, M. O., Y. Y. Wan, S. Sanjabi, et al. 2006. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 24: 99–146
16. Pontillo, A., E. C. Reis, B. L. Liphaus, et al. 2015. Inflammasome polymorphisms in juvenile systemic lupus erythematosus. Autoimmunity 16: 1–4
17. Silver, I., M. P. Heyes, J. C. Maize, et al. 1990. Scleroderma, fasciitis and eosinophilia associated with the ingestion of tryptophan. N. Engl. J. Med. 322: 874–881
18. D’Cruz, D. 2000. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol. Lett. 112–113: 421–432
19. Smith, C. A., A. C. Gough, P. N. Leigh, et al. 1992. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinsons disease. Lancet 6: 1375–1377
20. Sekigawa, I., T. Naito, K. Hira, et al. 2004. Possible mechanisms of gender bias in SLE: a new hypothesis involving a comparison of SLE with atopy. Lupus 13: 217–222
21. Wojtczak, A., M. Rychlik-Sych, E. Krochmalska-Ulacha, and J. Skrętkowicz. 2007. CYP2D6 phenotyping with dextromethorphan. Pharmacol. Rep. 59: 734–738
22. Sistonen, J., S. Fuselli, A. Levo, A. and Sajantila. 2005. CYP2D6 genotyping by a multiplex primer extension reaction. Clin. Chem. 51: 1291–1295
23. Mann, A., S. L. Miksys, A. Gaedigk, et al. 2012. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson’s disease patients. Neurobiol. Aging 33: 2160–2171
24. Singh, M., V. K. Khanna, R. Shukla, and D. Parmar. 2010. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease. Dis. Markers 28: 87–93
25. Sachse, C., G. Smith, M. J. Wilkie, et al. Colorectal Cancer Study Group. 2002. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23: 1839–1849
26. Nimura, Y., S. Yokoyama, M. Fujimori, et al. 1997. Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer 80: 852–857
27. Rychlik-Sych, M., J. Skrętkowicz, B. Gawrońska-Szklarz, et al. 2006. Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol. Rep. 58: 22–29
28. Skrętkowicz, K., J. Skrętkowicz, B. Gawrońska-Szklarz, et al. 2005. Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis. Eur. J. Clin. Pharmacol. 60: 773–778
29. Skrętkowicz, J., M. Barańska, and M. Rychlik-Sych. 2009. Genetic polymorphisms of CYP2D6 oxidation in patients with systemic sclerosis. Eur. J. Clin. Pharmacol. 65: 971–976
30. Sabbagh, N., D. Marez, V. Queyrel, et al. 1998. Genetic analysis of cytochrome P450 CYP2D6 polymorphism in patients with systemic lupus erythematosus. Pharmacogenetics 8: 191–194
31. Kortunay, S., A. Bozkurt, L. Bathum, et al. 1999. CYP2D6 polymorphism in systemic lupus erythematosus patients. Eur. J. Clin. Pharmacol. 55: 21–25
32. Skrętkowicz, J., M. Barańska, A. Kaczorowska, and M. Rychlik-Sych. 2011. Genetic polymorphisms of CYP2D6 oxidation in patients with systemic lupus erythematosus. Arch. Med. Sci. 5: 864–869
33. Von Schmiedeberg, S., E. Fritsche, A. C. Ronnau, et al. 1999. Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv. Exp. Med. Biol. 455: 147–152
34. Yen, J.H., Ch.-J. Chen, W.-Ch. Tsai, et al. 2003. Cytochrome P450 and manganese superoxide dismutase genes polymorphisms in lupus systemic erythematosus. Immunol. Lett. 90: 19–24
35. Kortunay, S., A. Bozkurt, L. Bathum, et al. 1999. CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus. Ann. Rheum. Dis. 58: 182–185
36. Povey, A., M. J. Guppy, M. Wood, et al. 2001. Cytochrome P2 polymorphism and susceptibility to scleroderma following exposure to organic solvents. Arthritis. Rheum. 44: 662–665
37. Barańska, M., B. Dziankowska-Bartkowiak, E. Waszczykowska, et al. 2012. Significance of genetic polymorphism of CYP2D6 in the pathogenesis of systemic sclerosis. Pharmacol. Rep. 64: 336–342
38. Niewiński, P., K. Orzechowska-Juzwenko, M. Hurkacz, et al. 2002. CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population. Eur. J. Clin. Pharmacol. 58: 533–535